Word

NAIO

Status

Pending

Status Code

630

Status Date

Monday, November 20, 2023

Serial Number

98252226

Mark Type

4000

Filing Date

Thursday, November 2, 2023

Trademark Owner History

Manifest Technologies Inc.

Classifications

44 Companion diagnostic for medical research and development; Companion diagnostic for clinical trials; Companion diagnostic for medical diagnostic decision making; Companion diagnostic for medical prognostic decision making; Companion diagnostic for treatment predictive decision making; Companion diagnostic for monitoring the status of a medical condition; Companion diagnostic for monitoring the safety of a therapeutic; Companion diagnostic for evaluating the efficacy of a therapeutic; Companion diagnostic for evaluating a pharmacodynamic biomarker; Companion diagnostic for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Companion diagnostic for evaluating the risk of developing a disorder of the central nervous system; Companion diagnostic for prevention of disorders of the central nervous system; Consulting services for others in the field of design, planning, and implementation project management of medical research and development; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Consulting services for others in the field of design, planning, and implementation project management of medical diagnostic decision making; Consulting services for others in the field of design, planning, and implementation project management of medical prognostic decision making; Consulting services for others in the field of design, planning, and implementation project management of treatment predictive decision making;Consulting services for others in the field of design, planning, and implementation project management of monitoring the status of a medical condition; Consulting services for others in the field of design, planning, and implementation project management of monitoring the safety of a therapeutic; Consulting services for others in the field of design, planning, and implementation project management of evaluating the efficacy of a therapeutic; Consulting services for others in the field of design, planning, and implementation project management of evaluating a pharmacodynamic biomarker; Consulting services for others in the field of design, planning, and implementation project management of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Consulting services for others in the field of design, planning, and implementation project management of evaluating the risk of developing a disorder of the central nervous system; Consulting services for others in the field of design, planning, and implementation project management of prevention of disorders of the central nervous system; Medical analysis services for others in the field of clinical trials; Medical analysis services for others in the field of medical diagnostic decision making; Medical analysis services for others in the field of medical prognostic decision making; Medical analysis services for others in the field of treatment predictive decision making; Medical analysis services for others in the field of monitoring the status of a medical condition; Medical analysis services for others in the field of monitoring the safety of a therapeutic; Medical analysis services for others in the field of evaluating the efficacy of a therapeutic; Medical analysis services for others in the field of evaluating a pharmacodynamic biomarker; Medical analysis services for others in the field of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Medical analysis services for others in the field of evaluating the risk of developing a disorder of the central nervous system; Medical analysis services for others in the field of prevention of disorders of the central nervous system; Medical analysis services for others in the field of medical research and development; Research and development in the field of biotechnology with a focus on disorders of the central nervous system

42 Software as a service (SaaS) for medical research and development; Software as a service (SaaS) for clinical trials; Software as a service (SaaS) for medical diagnostic decision making; Software as a service (SaaS) for medical prognostic decision making; Software as a service (SaaS) for treatment predictive decision making; Software as a service (SaaS) for monitoring the status of a medical condition; Software as a service (SaaS) for monitoring the safety of a therapeutic; Software as a service (SaaS) for evaluating the efficacy of a therapeutic; Software as a service (SaaS) for evaluating a pharmacodynamic biomarker; Software as a service (SaaS) for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Software as a service (SaaS) for evaluating the risk of developing a disorder of the central nervous system; Software as a service (SaaS) for prevention of disorders of the central nervous system; Software as a service (SaaS) for processing, managing, displaying and transmitting images of the central nervous system; Software as a service (SaaS) for dissemination of results or analyses related to any of the above; Cloud computing featuring software for scientific computing for use in the fields of medical research and development; Cloud computing featuring software for scientific computing for use in the fields of clinical trials; Cloud computing featuring software for scientific computing for use in the fields of medical diagnostic decision making; Cloud computing featuring software for scientific computing for use in the fields of medical prognostic decision making; Cloud computing featuring software for scientific computing for use in the fields of treatment predictive decision making; Cloud computing featuring software for scientific computing for use in the fields of monitoring the status of a medical condition; Cloud computing featuring software for scientific computing for use in the fields of monitoring the safety of a therapeutic; Cloud computing featuring software for scientific computing for use in the fields of evaluating the efficacy of a therapeutic; Cloud computing featuring software for scientific computing for use in the fields of evaluating a pharmacodynamic biomarker; Cloud computing featuring software for scientific computing for use in the fields of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Cloud computing featuring software for scientific computing for use in the fields of evaluating the risk of developing a disorder of the central nervous system; Cloud computing featuring software for scientific computing for use in the fields of prevention of disorders of the central nervous system; Cloud computing featuring software for scientific computing for use in the fields of processing, managing, displaying and transmitting images of the central nervous system; Cloud computing featuring software for scientific computing for disseminating results or analyses related to any of the above; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical research and development; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of clinical trials; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical diagnostic decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical prognostic decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of medical treatment predictive decision making; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of monitoring the status of a medical condition; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of monitoring the safety of a therapeutic; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating the efficacy of a therapeutic; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating a pharmacodynamic biomarker; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of evaluating the risk of developing a disorder of the central nervous system; Providing a web user interface featuring technology that enables users to share and process data for use in the fields of prevention of disorders of the central nervous system; Software-as-a-medical-device for medical research and development; Software-as-a-medical-device for clinical trials; Software-as-a-medical-device for medical diagnostic decision making; Software-as-a-medical-device for medical prognostic decision making; Software-as-a-medical-device for treatment predictive decision making; Software-as-a-medical-device for monitoring the status of a medical condition; Software-as-a-medical-device for monitoring the safety of a therapeutic; Software-as-a-medical-device for evaluating the efficacy of a therapeutic; Software-as-a-medical-device for evaluating a pharmacodynamic biomarker; Software-as-a-medical-device for evaluating a surrogate endpoint or reasonably likely surrogate endpoint; Software-as-a-medical-device for evaluating the risk of developing a disorder of the central nervous system; Software-as-a-medical-device for prevention of disorders of the central nervous system

Trademark Events

Nov 20, 2023

New Application Office Supplied Data Entered

Nov 6, 2023

New Application Entered